CNS PharmaceuticalsCNSP
13F holders, Q3 2025 (September 30)8holders +7
8new positions
1sold out
$9.00avg. 13F price*
At the end of Q3 2025, 8 institutions reported holding CNS Pharmaceuticals Inc. (CNSP) in their 13F filings, up 7 from Q2 2025. 8 opened new positions and 1 sold out. The largest holders were DRW Securities, LLC ($126K), UBS Group AG ($95K) and Morgan Stanley ($252).
- Company
- CNS Pharmaceuticals Inc.
- CUSIP
- 18978H508
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 8 | $222K |
| Exits | 1 | $11 |
All 13F filers, Q2 2025 → Q3 2025: 24,616 shares bought and 13 shares sold, net +24,603 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 8 holders
| DRW Securities, LLC | 0.01% | New | 14,050 | $126K |
| UBS Group AG | 0.00% | New | 10,520 | $95K |
| Morgan Stanley | 0.00% | New | 28 | $252 |
| Barrett & Company, Inc. | 0.00% | New | 8 | $72 |
| Bank of America Corp. | 0.00% | New | 4 | $36 |
| MAI Capital Management | 0.00% | New | 3 | $27 |
| Citigroup Inc. | 0.00% | New | 2 | $18 |
| Danske Bank A/S | 0.00% | New | 1 | $9 |
"% of holder's portfolio" is CNSP's weight in each manager's 13F, not the share of CNS Pharmaceuticals Inc. the manager owns.